207_Combined course Presentations

Overall survival RTOG 0617 vs RADITUX

Raditux trial

RTOG 0617 60 Gy

RTOG 0617 74 Gy

58% a

67% a

Mortality

64%*

1-year OS (%)

75%

78%

69%

2-year OS (%)

60%

53%

42%

5-year OS (%)

37%

-

-

Median OS (months)

32 months

29 months

20 months

*based on 5-years of follow-up a based on 2-years of follow-up